Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders

Group 1 - The Ademi Firm is investigating Tourmaline for possible breaches of fiduciary duty and other legal violations related to its transaction with Novartis [1] - Tourmaline shareholders will receive $48.00 per share in cash at closing, amounting to a total equity value of approximately $1.4 billion [1]